DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
November 28, 2023 08:05 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:10 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
June 01, 2022 08:00 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
March 21, 2022 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and...
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
March 04, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. “Dick has...
Adamis Pharmaceuticals Provides Business Update
June 01, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
May 17, 2021 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be...
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
May 12, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
April 15, 2021 16:39 ET
|
Adamis Pharmaceuticals Corporation
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call...